• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.87% Nasdaq Up0.34%

    ImmunoCellular Therapeutics, Ltd. (IMUC)

    -NYSE MKT
    0.70 Down 0.02(2.57%) 4:01PM EST
    Add to Portfolio
    ProfileGet Profile for:
    ImmunoCellular Therapeutics, Ltd.
    23622 Calabasas Road
    Suite 300
    Calabasas, CA 91302
    United States - Map
    Phone: 818-264-2300
    Fax: 818-224-5287
    Website: http://www.imuc.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:3

    Business Summary 

    ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of brain and ovarian cancers. Its lead product candidate includes ICT-107, a dendritic cell (DC) vaccine that completed completed Phase II testing trials for the treatment of glioblastoma multiforme (GBM). The company also develops other therapeutic DC vaccines, such as ICT-121 to treat recurrent GBM and other solid tumor cancers, as well as ovarian, pancreatic, and breast cancers; and ICT-140 that targets 7 tumor-associated antigens expressed on ovarian cancer cells. In addition, it has a differential immunization for antigen and antibody discovery platform for discovering monoclonal antibodies for therapeutic and diagnostic development. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on ImmunoCellular Therapeutics, Ltd.

    Corporate Governance 
    ImmunoCellular Therapeutics, Ltd.’s ISS Governance QuickScore as of Jul 1, 2013 is 8. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 2; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. John S. Yu M.D., Ph.D., 50
    Founder, Chairman, Chief Scientific Officer and Corp. Sec.
    201.00K796.00K
    Mr. Andrew Gengos , 50
    Chief Exec. Officer, Pres and Director
    527.00K0.00
    Mr. David E. Fractor CPA, 54
    Chief Financial Officer, Principal Accounting Officer, VP of Fin. and Treasurer
    174.00K0.00
    Dr. Anthony J. Gringeri Ph.D., 60
    Sr. VP of Strategic Resources
    141.00K0.00
    Mr. Sanford J. Hillsberg Esq., J.D., 66
    Co-Founder
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders